Semaglutide (marketed under brand names like Wegovy and Ozempic) and Tirzepatide (Mounjaro and Zepbound) are GLP-1 receptor agonists that help regulate appetite, insulin, and metabolism
[Abstract]2025 Aug:74:589-607
For a person weighing 250 pounds, this equates to losing 37 to 50 pounds
Lancet 2021 Phase 1b (cagri + sema) Enebo et al., n=96, 20 weeks
The Trump administration has cut thousands of jobs at the FDA in recent weeks, which could make it even harder for the agency to monitor compounding pharmacies
Experts discuss benefits, challenges of anti-obesity drugs in The Permanente Journal An expert panel discussion convened by The Permanente Journal explored the clinical, systemic, and societal impact of anti-obesity drugs like Ozempic and Wegovy